OvaScience Inc. (NASDAQ:OVAS)’s share price dropped 4.5% during trading on Wednesday . The stock traded as low as $5.80 and last traded at $5.91, with a volume of 250,708 shares trading hands. The stock had previously closed at $6.19.

OVAS has been the subject of several research reports. Zacks Investment Research upgraded shares of OvaScience from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a research report on Wednesday, August 10th. Leerink Swann reiterated a “hold” rating and set a $7.00 price objective (up previously from $6.00) on shares of OvaScience in a research report on Sunday, May 8th. JMP Securities reiterated a “neutral” rating on shares of OvaScience in a research report on Wednesday, August 10th. JPMorgan Chase & Co. lowered their price objective on shares of OvaScience from $9.00 to $8.00 and set a “neutral” rating for the company in a research report on Friday, August 5th. Finally, Credit Suisse Group AG reiterated a “sell” rating on shares of OvaScience in a research report on Tuesday, July 12th. One analyst has rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $10.98.

The stock’s market capitalization is $203.76 million. The stock has a 50 day moving average of $5.63 and a 200-day moving average of $7.08.

OvaScience (NASDAQ:OVAS) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.16. During the same period in the previous year, the firm posted ($0.64) EPS. The company earned $0.19 million during the quarter, compared to analysts’ expectations of $0.21 million. OvaScience’s revenue was up 530.0% compared to the same quarter last year. Equities research analysts expect that OvaScience Inc. will post ($2.66) earnings per share for the current fiscal year.

In related news, CEO Michelle Dipp purchased 425,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 1st. The stock was bought at an average price of $7.00 per share, with a total value of $2,975,000.00. Following the acquisition, the chief executive officer now owns 971,921 shares in the company, valued at $6,803,447. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.